Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Serum vitamin D concentrations among elderly people in Europe
van der Wielen, R. P. J., de Groot, L. C. P. G. M., van Staveren, W. A., Löwik, M. R. H., van den Berg, H., Haller, J., & Moreiras, O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91266-5 · Cited by 772
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Self-citationGenant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Cited by
Items 101–200 of 1,002
Johnell, O. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.985 · Cited by 230
Self-citationTreatment of established osteoporosis: a systematic review and cost-utility analysis
Kanis, J. A., Brazier, J. E., Stevenson, M., Calvert, N. W., & Lloyd Jones, M. (2002) · Health Technology Assessment · doi:10.3310/hta6290 · Cited by 229
Watts, N. B., Cooper, C., Lindsay, R., Eastell, R., Manhart, M. D., Barton, I. P., van Staa, T.-P., & Adachi, J. D. (2004) · Journal of Clinical Densitometry · doi:10.1385/jcd:7:3:255 · Cited by 229
Self-citationBlack, D. M., Bauer, D. C., Vittinghoff, E., Lui, L.-Y., Grauer, A., Marin, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 228
Self-citationAdherence to bisphosphonates therapy and hip fracture risk in osteoporotic women
Rabenda, V., Mertens, R., Fabri, V., Vanoverloop, J., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., & Reginster, J.-Y. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0506-x · Cited by 225
Self-citationDiscovery, Clinical Development, and Therapeutic Uses of Bisphosphonates
Licata, A. A. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e357 · Cited by 224
Harrington, J. T., Ste-Marie, L. G., Brandi, M. L., Civitelli, R., Fardellone, P., Grauer, A., Barton, I., & Boonen, S. (2004) · Calcified Tissue International · doi:10.1007/s00223-003-0042-4 · Cited by 223
Self-citationThe Alendronate Once-Weekly Study Group, & Rizzoli, R. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.11.1988 · Cited by 221
Händel, M. N., Cardoso, I., von Bülow, C., Rohde, J. F., Ussing, A., Nielsen, S. M., Christensen, R., Body, J.-J., Brandi, M. L., Diez-Perez, A., et al. (2023) · BMJ · doi:10.1136/bmj-2021-068033 · Cited by 219
Self-citationSalmon calcitonin: a review of current and future therapeutic indications
Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0490-1 · Cited by 216
The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil
Baccaro, L. F., Conde, D., Costa-Paiva, L., & Pinto-Neto, A. M. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s54614 · Cited by 216
Vertebral Fracture Assessment: The 2007 ISCD Official Positions
Schousboe, J. T., Vokes, T., Broy, S. B., Ferrar, L., McKiernan, F., Roux, C., & Binkley, N. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.008 · Cited by 215
Self-citationJaglal, S. B., Weller, I., Mamdani, M., Hawker, G., Kreder, H., Jaakkimainen, L., & Adachi, J. D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041231 · Cited by 213
Hasserius, R., Karlsson, M. K., Jónsson, B., Redlund-Johnell, I., & Johnell, O. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-2222-2 · Cited by 212
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004523.pub3 · Cited by 211
Eriksen, E. F., Melsen, F., Sod, E., Barton, I., & Chines, A. (2002) · Bone · doi:10.1016/s8756-3282(02)00869-4 · Cited by 211
Overview of treatment approaches to osteoporosis
Langdahl, B. L. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15024 · Cited by 207
Rizzoli, R., Reginster, J.-Y., Boonen, S., Bréart, G., Diez-Perez, A., Felsenberg, D., Kaufman, J.-M., Kanis, J. A., & Cooper, C. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9499-8 · Cited by 206
Self-citationHodsman, A. B., Hanley, D. A., Ettinger, M. P., Bolognese, M. A., Fox, J., Metcalfe, A. J., & Lindsay, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030768 · Cited by 205
Treating osteoporosis to prevent fractures: current concepts and future developments
Lorentzon, M. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12873 · Cited by 203
Seeman, E., Vellas, B., Benhamou, C., Aquino, J. P., Semler, J., Kaufman, J. M., Hoszowski, K., Varela, A. R., Fiore, C., Brixen, K., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060404 · Cited by 200
Self-citationEriksen, E. F., Díez-Pérez, A., & Boonen, S. (2014) · Bone · doi:10.1016/j.bone.2013.09.023 · Cited by 199
Conversion of a Fused Hipto Total Hip Arthroplasty
Joshi, A. B., Markovic, L., Hardinge, K., & Murphy, J. C. M. (2002) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-200208000-00008 · Cited by 199
Meunier, P. J., Roux, C., Ortolani, S., Diaz-Curiel, M., Compston, J., Marquis, P., Cormier, C., Isaia, G., Badurski, J., Wark, J. D., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0825-6 · Cited by 198
Self-citationFracture mortality: associations with epidemiology and osteoporosis treatment
Sattui, S. E., & Saag, K. G. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.125 · Cited by 195
Boonen, S., Orwoll, E. S., Wenderoth, D., Stoner, K. J., Eusebio, R., & Delmas, P. D. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081214 · Cited by 193
FRAX® with and without Bone Mineral Density
Kanis, J. A., McCloskey, E., Johansson, H., Oden, A., & Leslie, W. D. (2012) · Calcified Tissue International · doi:10.1007/s00223-011-9544-7 · Cited by 192
Adverse effects of bisphosphonates: current issues.
Diel, I., Bergner, R., & Grötz, K. A. (2007) · PubMed · Cited by 187
Unusual mid‐shaft fractures during long‐term bisphosphonate therapy
Odvina, C. V., Levy, S., Rao, S., Zerwekh, J. E., & Rao, D. S. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03581.x · Cited by 186
Delmas, P. D., Vrijens, B., Eastell, R., Roux, C., Pols, H. A. P., Ringe, J. D., Grauer, A., Cahall, D., Watts, N. B., & on behalf of the Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1526 · Cited by 186
Self-citationSimonelli, C., Killeen, K., Mehle, S., & Swanson, L. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.4.334 · Cited by 184
Efficacy of risedronate on clinical vertebral fractures within six months
Roux, C., Seeman, E., Eastell, R., Adachi, J., Jackson, R. D., Felsenberg, D., Songcharoen, S., Rizzoli, R., Munno, O. D., Horlait, S., et al. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125003125 · Cited by 184
Self-citation2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis
Briot, K., Cortet, B., Thomas, T., Audran, M., Blain, H., Breuil, V., Chapuis, L., Chapurlat, R., Fardellone, P., Feron, J.-M., et al. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.02.014 · Cited by 183
Self-citationMonitoring Osteoporosis Therapy: Bone Mineral Density, Bone Turnover Markers, or Both?
Bonnick, S. L., & Shulman, L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.12.020 · Cited by 182
Osteoporosis: underrated, underdiagnosed and undertreated
Nguyen, T. V., Center, J. R., & Eisman, J. A. (2004) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb05908.x · Cited by 181
Osteoclastogenesis, Bone Resorption, and Osteoclast-Based Therapeutics
Zaidi, M., Blair, H. C., Moonga, B. S., Abe, E., & Huang, C. L.-H. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.4.599 · Cited by 180
Boonen, S., McClung, M. R., Eastell, R., El‐Hajj Fuleihan, G., Barton, I. P., & Delmas, P. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52506.x · Cited by 179
Self-citationPreventing fractures in elderly people
Woolf, A. D., & Åkesson, K. (2003) · BMJ · doi:10.1136/bmj.327.7406.89 · Cited by 178
Bisphosphonates for the prevention and treatment of osteoporosis
Maraka, S., & Kennel, K. A. (2015) · BMJ · doi:10.1136/bmj.h3783 · Cited by 178
Assessment of prevalent and incident vertebral fractures in osteoporosis research
Genant, H. K., & Jergas, M. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1348-1 · Cited by 178
Low Incidence of Anti-Osteoporosis Treatment After Hip Fracture
Rabenda, V., Vanoverloop, J., Fabri, V., Mertens, R., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., & Reginster, J. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.g.00864 · Cited by 178
Self-citationBoonen, S., Laan, R., Barton, I. P., & Watts, N. B. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1945-x · Cited by 177
Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range
El-Hajj Fuleihan, G., Bouillon, R., Clarke, B., Chakhtoura, M., Cooper, C., McClung, M., & Singh, R. J. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2536 · Cited by 176
Borah, B., Dufresne, T. E., Chmielewski, P. A., Johnson, T. D., Chines, A., & Manhart, M. D. (2004) · Bone · doi:10.1016/j.bone.2003.12.013 · Cited by 176
Silverman, S. L., Watts, N. B., Delmas, P. D., Lange, J. L., & Lindsay, R. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0274-z · Cited by 174
Drug induced osteonecrosis of the jaw
Hamadeh, I. S., Ngwa, B. A., & Gong, Y. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.007 · Cited by 173
Lange, U., Teichmann, J., Müller-Ladner, U., & Strunk, J. (2005) · Rheumatology · doi:10.1093/rheumatology/kei082 · Cited by 171
Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis
Bilezikian, J. P. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.003 · Cited by 170
Naylor, K. E., Jacques, R. M., Paggiosi, M., Gossiel, F., Peel, N. F. A., McCloskey, E. V., Walsh, J. S., & Eastell, R. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3145-7 · Cited by 170
Self-citationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Ringe, J. D., Faber, H., Farahmand, P., & Dorst, A. (2006) · Rheumatology International · doi:10.1007/s00296-005-0004-4 · Cited by 169
Borah, B., Dufresne, T. E., Ritman, E. L., Jorgensen, S. M., Liu, S., Chmielewski, P. A., Phipps, R. J., Zhou, X., Sibonga, J. D., & Turner, R. T. (2006) · Bone · doi:10.1016/j.bone.2006.01.161 · Cited by 168
Aging Bone and Osteoporosis: Strategies for Preventing Fractures in the Elderly
Ettinger, M. P. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.18.2237 · Cited by 167
2018 update of French recommendations on the management of postmenopausal osteoporosis
Briot, K., Roux, C., Thomas, T., Blain, H., Buchon, D., Chapurlat, R., Debiais, F., Feron, J. M., Gauvain, J. B., Guggenbuhl, P., et al. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.02.009 · Cited by 167
Self-citationMashiba, T., Mori, S., Komatsubara, S., Cao, Y., Manabe, T., Norimatsu, H., & Burr, D. B. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/bf03026321 · Cited by 165
Davis, S., Simpson, E., Hamilton, J., James, M. M.-S., Rawdin, A., Wong, R., Goka, E., Gittoes, N., & Selby, P. (2020) · Health Technology Assessment · doi:10.3310/hta24290 · Cited by 164
Marcus, R., Wong, M., Heath, H., & Stock, J. L. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0453 · Cited by 164
Watts, N. B., Geusens, P., Barton, I. P., & Felsenberg, D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050814 · Cited by 164
Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures
Siminoski, K. G., Jiang, G., Adachi, J. D., Hanley, D. A., Cline, G. A., Ioannidis, G., Hodsman, A. B., Josse, R. G., Kendler, D. L., Olszynski, W. P., et al. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1709-z · Cited by 164
Self-citationTolerability and compliance with risedronate in clinical practice
Hamilton, B., McCoy, K., & Taggart, H. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1370-3 · Cited by 163
Dufresne, T. E., Chmielewski, P. A., Manhart, M. D., Johnson, T. D., & Borah, B. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-2104-4 · Cited by 162
Borah, B., Dufresne, T. E., Chmielewski, P. A., Gross, G. J., Prenger, M. C., & Phipps, R. J. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1139 · Cited by 162
Bisphosphonates: how do they work?
Papapoulos, S. E. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.001 · Cited by 162
Maricic, M., Adachi, J. D., Sarkar, S., Wu, W., Wong, M., & Harper, K. D. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1140 · Cited by 161
Marx, R. E. (2007) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2007.07.008 · Cited by 160
Leeming, D. J., Alexandersen, P., Karsdal, M. A., Qvist, P., Schaller, S., & Tankó, L. B. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0174-3 · Cited by 160
Reid, D. M., Adami, S., Devogelaer, J.-P., & Chines, A. A. (2001) · Calcified Tissue International · doi:10.1007/s00223-001-1060-8 · Cited by 160
Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis
Kranenburg, G., Bartstra, J. W., Weijmans, M., de Jong, P. A., Mali, W. P. T. M., Verhaar, H. J. J., Visseren, F. L. J., & Spiering, W. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.039 · Cited by 160
Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis
Belaya, Z. E., Belova, K. Y., Biryukova, E. V., Dedov, I. I., Dzeranova, L. K., Drapkina, O. M., Dreval', A. V., Dubovitskaya, Т. A., Dudinskaya, Е. N., Ershova, O. B., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12930 · Cited by 160
Allen, M. R., Gineyts, É., Leeming, D. J., Burr, D. B., & Delmas, P. D. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0533-7 · Cited by 160
Middle East and North Africa consensus on osteoporosis.
Maalouf, G., Gannagé‐Yared, M., Ezzedine, J., Larijani, B. A., Badawi, S., Rached, A., Zakroui, L., Masri, B. K., Azar, E., Saba, E., et al. (2007) · PubMed · Cited by 158
Vertebral Fracture Assessment: The 2005 ISCD Official Positions
Vokes, T., Bachman, D. M., Baim, S., Binkley, N., Broy, S. B., Ferrar, L., Lewiecki, E. M., Richmond, B. J., & Schousboe, J. T. (2006) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2006.05.006 · Cited by 157
Bonnick, S., Saag, K. G., Kiel, D. P., McClung, M., Hochberg, M., Burnett, S.-A. M., Sebba, A., Kagan, R., Chen, E., Thompson, D. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2602 · Cited by 145
Hodgson, S. F., Nb, W., Bilezikian, J. P., Clarke, B. L., Gray, T. K., Johnston, C. C., Kleerekoper, M., Lindsay, R. S., Luckey, M. M., McClung, M. R., et al. (2001) · Endocrine Practice · Cited by 157
Differing effects of denosumab and alendronate on cortical and trabecular bone
Zebaze, R. M., Libanati, C., Austin, M., Ghasem-Zadeh, A., Hanley, D. A., Zanchetta, J. R., Thomas, T., Boutroy, S., Bogado, C. E., Bilezikian, J. P., et al. (2014) · Bone · doi:10.1016/j.bone.2013.11.016 · Cited by 155
Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion
Migliorini, F., Colarossi, G., Baroncini, A., Eschweiler, J., Tingart, M., & Maffulli, N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1851192 · Cited by 155
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D., Avgerinou, C., Bowden, J., Cooper, C. C., Douglas, L., Edwards, J., Gittoes, N. J. L., Harvey, N. C., Kanis, J. A., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01588-3 · Cited by 157
Chapurlat, R. D., Arlot, M., Burt-Pichat, B., Chavassieux, P., Roux, J. P., Portero-Muzy, N., & Delmas, P. D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070609 · Cited by 154
Greenspan, S. L., Resnick, N. M., & Parker, R. A. (2003) · JAMA · doi:10.1001/jama.289.19.2525 · Cited by 153
A method to assess the proportion of treatment effect explained by a surrogate endpoint
Li, Z., Meredith, M. P., & Hoseyni, M. S. (2001) · Statistics in Medicine · doi:10.1002/sim.984 · Cited by 153
Dunstan, C. R., Felsenberg, D., & Seibel, M. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0688 · Cited by 153
Patient Adherence to Osteoporosis Medications: Problems, Consequences and Management Strategies
Papaioannou, A., Kennedy, C. C., Dolovich, L., Lau, E., & Adachi, J. D. (2007) · Drugs & Aging · doi:10.2165/00002512-200724010-00003 · Cited by 151
Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis
Kanis, J., Stevenson, M., McCloskey, E., Davis, S., & Lloyd-Jones, M. (2007) · Health Technology Assessment · doi:10.3310/hta11070 · Cited by 151
Roux, C., Reginster, J., Fechtenbaum, J., Kolta, S., Sawicki, A., Tulassay, Z., Luisetto, G., Padrino, J. M., Doyle, D., Prince, R. L., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060101 · Cited by 151
Self-citationPersistence with weekly alendronate therapy among postmenopausal women
Lo, J. C.-M., Pressman, A. R., Omar, M. A., & Ettinger, B. B. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0085-2 · Cited by 150
Grbic, J. T., Landesberg, R., Lin, S., Mesenbrink, P. G., Reid, I. R., Leung, P., Casas, N., Recknor, C. P., Hua, Y., Delmas, P. D., et al. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0017 · Cited by 150
Carbone, L. D., Tylavsky, F. A., Cauley, J. A., Harris, T. B., Lang, T. F., Bauer, D. C., Barrow, K. D., & Kritchevsky, S. B. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.10.1795 · Cited by 135
Safety issues with bisphosphonate therapy for osteoporosis
Suresh, E., Pazianas, M., & Abrahamsen, B. (2013) · Rheumatology · doi:10.1093/rheumatology/ket236 · Cited by 149
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?
Cryer, B., & Bauer, D. C. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.10.1031 · Cited by 148
Fragility fractures of the pelvis
Soles, G., & Ferguson, T. A. (2012) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-012-9128-9 · Cited by 148
Borah, B., Ritman, E. L., Dufresne, T. E., Jorgensen, S. M., Liu, S., Sacha, J. P., Phipps, R. J., & Turner, R. T. (2005) · Bone · doi:10.1016/j.bone.2005.03.017 · Cited by 148
The North American Menopause Society (2002) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200203000-00003 · Cited by 148
Bisphosphonates for postmenopausal osteoporosis
Eastell, R., Walsh, J., Watts, N. B., & Siris, E. S. (2011) · Bone · doi:10.1016/j.bone.2011.02.011 · Cited by 147
Self-citationDeardorff, W. J., Cenzer, I. S., Nguyen, B., & Lee, S. J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.6745 · Cited by 146
Perspective: Reconsidering the Effects of Antiresorptive Therapies in Reducing Osteoporotic Fracture
Chesnut, C. H., & Rosen, C. J. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.12.2163 · Cited by 133
McCloskey, E., Selby, P., Davies, M., Robinson, J., Francis, R. M., Adams, J., Kayan, K., Beneton, M., Jalava, T., Pylkkänen, L., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040116 · Cited by 127
McCloskey, E. V., Johansson, H., Odén, A., Vasireddy, S., Kayan, K., Pande, K. C., Jalava, T., & Kanis, J. А. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0786-9 · Cited by 144
Baim, S., & Miller, P. D. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090203 · Cited by 143
Risedronate Prevents New Vertebral Fractures in Postmenopausal Women at High Risk
Watts, N. B., Josse, R. G., Hamdy, R. C., Hughes, R. A., Manhart, M. D., Barton, I., Calligeros, D., & Felsenberg, D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020400 · Cited by 115
Bruyère, O., Roux, C., Detilleux, J. C., Slosman, D. O., Spector, T. D., Fardellone, P., Brixen, K., Devogelaer, J., Díaz Curiel, M., Albanese, C. V., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2758 · Cited by 143
Self-citation
Metadata
- Authors
- Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R.
- Affiliations
- University of Liège (BE)
- The University of Sydney (AU)
- Hôpital Cochin (FR)
- University of Florence (IT)
- Procter & Gamble (United States) (US)
- University of Sheffield (GB)
- Venue
- Osteoporosis International
- Published
- 2000-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1526826623
- Cited by
- 1,580
- References
- 29
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 27 · 2016: 44 · 2015: 50 · 2014: 47 · 2013: 69 · 2012: 66
- FWCI
- 78.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, postmenopausal osteoporosis, vertebral fractures, fracture prevention, bisphosphonates, bone mineral density, non-vertebral fractures, calcium and vitamin D supplementation, gastrointestinal adverse effects, drug safety
- MeSH terms
- Risedronic Acid, Aged, Aged, 80 and over, Algorithms, Australia, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Middle Aged, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.